Siligmueller & Norvid Wealth Advisors’s Edwards Lifesciences EW Stock Holding History

Siligmueller & Norvid Wealth Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$382K	Buy	+4,911	New	+$384K	0.17%	103

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Siligmueller & Norvid Wealth Advisors's EW Position: Q3 2025 in Review

Siligmueller & Norvid Wealth Advisors opened a new position in Edwards Lifesciences (EW) in Q3 2025: 4,911 shares worth $382K. The stake represents 0.17% of the portfolio and ranks #103 among its holdings.

1,253 funds tracked by Wall St. Rank hold EW as of Q3 2025.

Siligmueller & Norvid Wealth Advisors held 4,911 shares of Edwards Lifesciences worth $382K as of Q3 2025.
Edwards Lifesciences was a new Siligmueller & Norvid Wealth Advisors position in Q3 2025.
Edwards Lifesciences made up 0.17% of Siligmueller & Norvid Wealth Advisors's portfolio in Q3 2025, its #103 holding.
1,253 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Siligmueller & Norvid Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.